Oral treatment with desipramine improves breathing and life span in Rett syndrome mouse model

• DOI: 10.1016/j.resp.2007.08.009
• Publication Date: 2007-08-27T11:10:10Z
• Authors: Sébastien Zanella; Saida Mebarek; Anne-Marie Lajard; Nathalie Picard; Mathias Dutschmann; Gérard Hilaire
• Keywords: Mice, Knockout; Medulla Oblongata; 0303 health sciences; Apnea; Methyl-CpG-Binding Protein 2; Longevity; Desipramine; Antidepressive Agents, Tricyclic; 3. Good health; Mice, Inbred C57BL; Plethysmography; Mice; Norepinephrine; 03 medical and health sciences; Microcephaly; Respiratory Mechanics; Rett Syndrome; Animals; Female; Locomotion

Rett syndrome is a neurodevelopmental disease due to Mecp2 gene mutations that is associated to complex neurological symptoms, with bioaminergic deficits and life-threatening apneas related to sudden and unexpected death. In male mice, Mecp2-deficiency similarly induces medullary bioaminergic deficits, severe apneas and short life span. Here, we show that long-term oral treatment of Mecp2-deficient male mice with desipramine, an old drug of clinical use known to block norepinephrine uptake and to strengthen its synaptic effects, significantly alleviates their breathing symptoms and prolongs their life span. Although these mouse results identify desipramine as the first oral pharmacological treatment potentially able to alleviate breathing symptoms of Rett syndrome, we recommend further studies of desipramine effects in Mecp2-deficient mice before attempting any clinical trials in Rett patients.